Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
Mel Snyder, Healthcare Commercialization and Strategy Advisor at ProClinica Inc., shared a post on LinkedIn:
“Now, more than 5000 American children with sickle cell disease can access a genetic cure for a disease that causes pain, organ damage, loss of school days, ans limited participation in sports and other childhood activities.
Possibly more important: The FDA’s action on Casgevy/Sickle-Cell Disease suggests a more liberal view of extending to pediatric patients other genetic cures until now reserved for adults.
Since the vast majority of genetic diseases first appear in infants, this FDA action may encourage more investment in public and private biopharmas working on agents for other genetic diseases first seen in childhood.”
Stay updated with Hemostasis Today.
-
Jul 23, 2026, 15:43Lorna Knight: The Next Frontier in Sickle Cell Disease Is Access
-
Jul 23, 2026, 15:29Ben Kleinstiver: Overcoming a Major Barrier to Scalable Gene Editing
-
Jul 23, 2026, 15:28Modernizing DIC Diagnosis in Cirrhosis: Building an International Registry for Precision Hemostasi
-
Jul 23, 2026, 14:32Saneha Anjum Shaikh: Why Antibody Screening Must Be Standard Practice in Modern Blood Banking
-
Jul 23, 2026, 14:00Ron Vezina: Canadian Blood Services Issues Urgent Donation Appeal
-
Jul 23, 2026, 13:46Sebastian Szmit: Understanding Troponins in Modern Cardio-Oncology
-
Jul 23, 2026, 13:41Colleen Grady: Why Normal Hemoglobin Does Not Exclude Iron Deficiency
-
Jul 23, 2026, 13:22Jacob Kelly: AHA Review Highlights Coffee’s Cardiovascular Benefits
-
Jul 23, 2026, 13:01Sally Mandour: Automated Blood Indices Enhance IDA Diagnosis in Cirrhotic Patients